A subsidiary of Swiss drug giant Novartis AG announced plans Tuesday to build a targeted radioligand therapy plant at Purdue Research Park near Indianapolis International Airport.
2020 Innovation Issue: Brothers share a knack for creating life sciences companies
Philip and Martin Low’s latest venture, Eradivir, was incorporated in February to develop a treatment that would fight the influenza virus, but COVID-19 prompted a tweak to the business plan.Read More
Crowne Plaza near Indy airport being used as COVID-19 treatment site
State officials declined to provide details on specifically how the hotel is being used—including whether it is a treatment site for homeless individuals—to protect patient privacy.Read More
First 16 Tech office building set to open in June; Innovation Hub to follow
The long-planned $500 million project is at a pivotal moment—one its organizers say could serve as a catalyst for tremendous growth at the 50-acre campus and for central Indiana overall.Read More
Butler researchers point to way to stop deadly coronavirus from spreading
Dr. Christopher Stobart and his students are focusing on an enzyme in the virus that could inhibit its replication, and plan to submit the findings to a virology journal in coming months.Read More
In Touch Pharmaceuticals serves long-term-care facilities in Illinois, Indiana and Michigan. It credits its system for helping clients reduce medication errors, cut waste and reduce costs.
West Lafayette-based Bioanalytical Systems’ latest executive departure comes amid recent signs of stability, turnaround and growth for a company that just three years ago was on the verge of sinking.
The pharmaceutical company said the Roundup settlement would “bring closure to approximately 75%” of the current 125,000 claims against subsidiary Monsanto.
The Hoosier state has 17,093 industry jobs spread out among 69 companies, from Indianapolis-based drugmaker Eli Lilly and Co. to startups scattered around the state, but mostly in clusters near research universities.
The Indianapolis-based insurer says the treatments are “investigational”—or still under clinical study—but a California woman claims the electrical stimulation is FDA-approved and supported by numerous studies.
Taltz rang up sales of $1.3 billion last year, an increase of 46%, making it Lilly’s fastest-growing drug. An estimated 137,000 patients have been treated with Taltz worldwide since its launch four years ago.
The design of the long-anticipated project was originally set to be unveiled by the end of 2018, but has been delayed several times—most recently this spring, as the pandemic began to sweep across the United States.
Gov. Eric Holcomb lifted the ban effective Monday, with some caveats, such as making sure that hospitals keep enough personnel and personal protective equipment on hand for COVID-19 patients.
The two technologies are different, but the goal of both is to provide a result within 40 minutes. The researchers say they are working with manufacturers to develop the products, which they hope will retail for $5 or less.
Baricitinib, also known under the brand name Olumiant, is approved in more than 65 countries as a treatment for adults with moderately to severely active rheumatoid arthritis.
Indiana has been undergoing a huge shift in psychiatric care in recent years, but still doesn’t have the resources to deal with patients suffering from ailments ranging from anxiety to schizophrenia.
The main manufacturer of a pesticide used for decades on a wide array of crops, including strawberries, corn and citrus, said Thursday it will stop making the product, which some activists have said is linked to neurological problems in children.
The report, issued Monday by researchers at the Fairbanks School of Public Health at IUPUI, is the latest commentary on Indiana’s poor report card on health care.
The Indianapolis drugmaker quietly terminated a collaboration with NextCure Inc. after spending $40 million on an up-front fee and equity investment, and with little to show from the partnership.
After raking in record amounts of venture capital funding in 2017 and 2018, Indiana life science companies saw funding drop last year by double-digits, while the average deal amount dipped sharply as well.
Dr. Anantha Shekhar, a nationally recognized health sciences researcher and entrepreneur, has played a major role in boosting research funding at IU, where he has worked since 1989 in numerous leadership roles.
The year didn’t feature any hostile takeovers or huge disasters. But a lot of companies made big strides in 2019, including Eli Lilly and Co., Corteva and Elanco. And many rejoiced when Washington ended a 2.3% tax on thousands of medical devices.
The repeal ends a 2.3% tax on thousands of medical devices, from stents and catheters to pacemakers and MRI machines. Indiana is home to 155 device-makers, ranging from small metal shops to multibillion-dollar manufacturers.
To satisfy House Democrats, the Trump administration removed a provision that would have given the makers of ultra-expensive biologic drugs 10 years of protection from less expensive knockoffs.